BrainsWay Ltd. (BWAY) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets.
Analysis Summary
BrainsWay Ltd. reported revenue of $52.2M in the most recent fiscal year, growing at a 5-year CAGR of 18.8%.
Trailing-twelve-month margins: gross margin 75.3%, operating margin 12.2%, net margin 14.6%.
At the current price of $13.46, BWAY trades at a P/E of 54.41 and an ROE of 12.69%. Market capitalisation stands at $528M.
Balance sheet quality for BWAY: current ratio of 3.8, net cash position of $62.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $16.4M represents 215% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $13.46 |
| Market Cap | $528M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 54.41 |
| Price / Book | 6.67 |
| EV / EBITDA | 73.40 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 12.69% |
| Return on Invested Capital | 7.71% |
| Return on Assets | 7.76% |
| Gross Margin | 75.33% |
| Operating Margin | 12.18% |
| Net Margin | 14.61% |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 3.59 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.87 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BWAY | BrainsWay Ltd. | $528M | 54.41 | 6.67 | 12.7% |
| ALC | Alcon Inc. | $32.2B | 51.85 | 1.52 | |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | |||
| 0A05.L | Medacta Group S.A. | $2.3B |
Price Performance
| 1 month | -8.19% |
| 3 months | -9.60% |
| Year-to-date | +41.54% |
| 1 year | +67.62% |
| 3 years | +550.24% |
52-Week Range
| 52-week High | $17.40 |
| 52-week Low | $7.14 |
| Avg Volume (90d) | 125K |
Related companies: CERS · CVRX · DCTH · MASS · NPCE · RXST · SENS
Explore sector: Healthcare · Medical - Specialties
More sections of BWAY: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks